Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.

MLA

Kennedy, Glen A., et al. “Addition of Interleukin-6 Inhibition with Tocilizumab to Standard Graft-versus-Host Disease Prophylaxis after Allogeneic Stem-Cell Transplantation: A Phase 1/2 Trial.” The Lancet. Oncology, vol. 15, no. 13, Dec. 2014, pp. 1451–59. EBSCOhost, https://doi.org/10.1016/S1470-2045(14)71017-4.

APA

Kennedy, G. A., Varelias, A., Vuckovic, S., Le Texier, L., Gartlan, K. H., Zhang, P., Thomas, G., Anderson, L., Boyle, G., Cloonan, N., Leach, J., Sturgeon, E., Avery, J., Olver, S. D., Lor, M., Misra, A. K., Hutchins, C., Morton, A. J., Durrant, S. T., … Hill, G. R. (2014). Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. The Lancet. Oncology, 15(13), 1451–1459. https://doi.org/10.1016/S1470-2045(14)71017-4

Chicago

Kennedy, Glen A, Antiopi Varelias, Slavica Vuckovic, Laetitia Le Texier, Kate H Gartlan, Ping Zhang, Gethin Thomas, et al. 2014. “Addition of Interleukin-6 Inhibition with Tocilizumab to Standard Graft-versus-Host Disease Prophylaxis after Allogeneic Stem-Cell Transplantation: A Phase 1/2 Trial.” The Lancet. Oncology 15 (13): 1451–59. doi:10.1016/S1470-2045(14)71017-4.